Antibiotics Medicine Intelligence — Pakistan

Generated 2026-08-01T22:55:09.716203 · 99 molecules mapped

Market Calibration (IQVIA Q1 2025 Ground-Truth)

Metric	Value
Total Market Value	1.049 trillion PKR ($3.77B)
Unit Sales (Q1)	3.77 billion units (+3.63% YoY, +5.49% CAGR)
CAGR 2021-2025	+19.09%
NAT/MNC Split	NATs: 816.74 billion PKR (+21.07% YoY, +20.44% CAGR) \| MNCs: 232.49 billion PKR (+19.04% YoY, +14.88% CAGR)
Price vs Volume Growth	60% of growth from price hikes, not volume

Ferozsons 2025 Benchmark

Revenue	PKR 13.858 billion
Net Profit	PKR 528 million
Net Margin	3.8%
Brands	130+
Market Cap	PKR 16.937 billion

Calibration factor: 4.5 applied to all demand proxy estimates. Demand type: Annualized unit estimates scaled to IQVIA Q1 baseline

Unit definition: Annual units per molecule category (proxy demand, not confirmed sales)

Top Molecules by Crowding

Molecule	Brands	Companies	Essential	Crowded
Ciprofloxacin	1233	400	✓	✓
Cefixime	1027	338	✓	✓
Azithromycin	992	349	✓	✓
Levofloxacin	889	381	✓	✓
Metronidazole	550	260	✓	✓
Amoxicillin	342	105	✓	✓
Cephalexin	300	129		✓
Doxycycline	155	121	✓	✓
Ciprofloxacin Taste Masked	48	28
Doxycycline Hyclate	44	33

Launch Opportunity Shortlist

Molecule	Score	Confidence	Supply Gap	Price Room
Azithromycin Compacted	59	65%	60	100
Amoxicillin Mg	59	65%	60	100
Amoxicillin Base	59	90%	32	100
Amoxicillin 1 Gm	59	65%	60	100
Levofloxacin 750 Gm	59	65%	60	100
Amoxicillin Amoxicillin	57	90%	40	100
Ciprofloxacinashcl	57	90%	40	100
Cephalexin Cephalexin	53	65%	60	70
Cefixime Hydrate	53	90%	60	48
Ciprofloxacin 200	53	65%	60	70
Amoxicillin Clavulanic Acid 50	53	65%	60	74
Amoxicillin 500mgclavulanicacid	53	65%	60	74
Amoxicillinas 250mgclavulanicacidaspotassium	53	65%	60	74
Metronidazole Mg	52	65%	40	100
Levofloxacin Base	52	65%	40	100

Launch Simulator (Monte Carlo, 10 000 draws)

All assumptions printed below — assumptions shown = credibility; assumptions hidden = snake oil.

Competitor response: each existing brand has a 30% chance of cutting price by 10-25% in response to a new entrant (based on observed DVAGO price-volatility patterns).

Price elasticity: demand scales linearly with price difference vs median category price (simplified; real elasticity requires time-series data).

Market size: total addressable units = sum of all brand pack-sizes × estimated annual velocity (conservative: 1 strip/month per brand).

Regulatory: 6-month approval lag assumed; no DRAP ceiling breach risk modelled (all prices compared against ceiling).

No real sales data used — all volumes are demand-proxy estimates.

Molecule	Brands	Viable Band %	Loss-Leader %	Supply Gap
Metronidazole	550	0.0%	100.0%	45
Ciprofloxacin	1233	0.0%	100.0%	45
Doxycycline	155	0.0%	100.0%	45
Amoxicillin	342	0.0%	100.0%	45
Levofloxacin	889	0.0%	100.0%	25
Cefixime	1027	0.0%	100.0%	45
Azithromycin	992	0.0%	100.0%	45
Cephalexin	300	0.0%	100.0%	20
Metronidazole Benzoate	35	1.8%	98.2%	0
Doxycycline Hyclate	44	0.3%	99.7%	0
Amoxicillin Amoxicillin	5	84.2%	13.8%	40
Benzyl Metronidazole	3	91.1%	4.9%	25
Ciprofloxacin Hci	7	74.8%	24.1%	25
Amoxicillin Sodium	19	22.6%	77.4%	0
Cephalexin Cephalexin	2	91.0%	2.2%	60

Demand Proxy Engine (Honest Ranges)

Low / base / high estimates — not real sales. All assumptions shown. Calibrated against IQVIA Q1 2025 data.

Molecule	Low	Base	High	Confidence	Calibrated	Why
Metronidazole	495,000	1,237,500	4,331,250	high	✓	550 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Ciprofloxacin	1,109,700	2,774,250	9,709,875	high	✓	1233 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Doxycycline	139,500	348,750	1,220,625	high	✓	155 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Amoxicillin	307,800	769,500	2,693,250	high	✓	342 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Levofloxacin	800,100	2,000,250	7,000,875	high	✓	889 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=25, crowded=1, essential=1
Cefixime	924,300	2,310,750	8,087,625	high	✓	1027 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Azithromycin	892,800	2,232,000	7,812,000	high	✓	992 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=45, crowded=1, essential=1
Cephalexin	270,000	675,000	2,362,500	high	✓	300 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=20, crowded=1, essential=0
Antibiotics	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=85, crowded=0, essential=1
Benzoyl Metronidazole	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole Benzoate	31,500	78,750	275,625	medium	✓	35 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=0, crowded=0, essential=0
Doxycycline Hyclate	39,600	99,000	346,500	medium	✓	44 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=0, crowded=0, essential=0
Amoxicillin Amoxicillin	4,500	11,250	39,375	low	✓	5 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=40, crowded=0, essential=0
Benzyl Metronidazole	2,700	6,750	22,680	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=93, gap=25, crowded=0, essential=0
Ciprofloxacin Hci	6,300	15,750	35,595	low	✓	7 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=38, gap=25, crowded=0, essential=0
Ciprofloxacin H2o	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole Base	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Doxycycline Base	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillin Sodium	17,100	42,750	149,625	medium	✓	19 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=0, crowded=0, essential=0
Cephalexin Cephalexin	1,800	4,500	13,050	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=70, gap=60, crowded=0, essential=0
Levofloxacin Levofloxacin	2,700	6,750	13,095	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=22, gap=40, crowded=0, essential=0
Amoxicillin Trhydrate	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Doxycycline Hycalte	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Azithromycin Azithromycin Dihydarte	5,400	13,500	40,500	low	✓	6 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=75, gap=12, crowded=0, essential=0
Cefixime Cefixime	1,800	4,500	7,920	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=13, gap=40, crowded=0, essential=0
Azithromycin Azithromycin	1,800	4,500	7,470	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=8, gap=60, crowded=0, essential=0
Metronidazoleasbenzonate	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin Na	2,700	6,750	13,500	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=25, gap=60, crowded=0, essential=0
Ciprofloxacin Base	12,600	31,500	110,250	medium	✓	14 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=0, crowded=0, essential=0
Ciprofloxacin Ciprofloxacin	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole B P	3,600	9,000	31,500	low	✓	4 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=25, crowded=0, essential=0
Azithromycin Compacted	1,800	4,500	15,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=60, crowded=0, essential=0
Azithromycin Dehydrate	4,500	11,250	23,850	low	✓	5 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=31, gap=12, crowded=0, essential=0
Ciprofloxacinashcl	3,600	9,000	31,500	low	✓	4 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=40, crowded=0, essential=0
Levofloxacinas	4,500	11,250	38,025	low	✓	5 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=94, gap=12, crowded=0, essential=0
Levofloxacin Hemydrate	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillinas	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacinaslactate	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Cefixime Hydrate	2,700	6,750	16,605	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=60, crowded=0, essential=0
Clavulanic Acid Amoxicillin	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin 200	1,800	4,500	13,050	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=70, gap=60, crowded=0, essential=0
Metronidazole 500	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillintrihydrateequivalenttoamoxcillinbase	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillintrihydrateequivalenttoamoxicillinbase	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin Taste Masked	43,200	108,000	378,000	medium	✓	48 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=0, crowded=0, essential=0
Ciprofloxacin Taste Masked Ciprofloxacin	1,800	4,500	6,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin Taste Masked Micro	3,600	9,000	18,540	low	✓	4 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=28, gap=25, crowded=0, essential=0
Microencapsulated Ciprofloxacin	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole Benzoyl	2,700	6,750	11,070	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=7, gap=25, crowded=0, essential=0
Azithromycin Azithromycin Taste Masked	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Azithromycin 250 0	1,800	4,500	8,640	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=21, gap=40, crowded=0, essential=0
Cefixime Trihydate	2,700	6,750	11,745	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=12, gap=60, crowded=0, essential=0
Ceftazidimeusp Antibiotic	900	2,250	5,310	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=43, gap=60, crowded=0, essential=0
Azithromycin 1 Gm	1,800	4,500	12,600	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=65, gap=40, crowded=0, essential=0
Ciprofloxacin Mg	3,600	9,000	22,140	low	✓	4 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=12, crowded=0, essential=0
Amoxicillinsodium1 0gm Potassiumclavulanate0 2gm	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin Ciprofloxacin Ciprofloxacin	900	2,250	5,760	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=53, gap=60, crowded=0, essential=0
Amoxicillin Mg	900	2,250	7,875	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=60, crowded=0, essential=0
Metronidazole Mg	1,800	4,500	15,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=40, crowded=0, essential=0
Levofloxacin Base	1,800	4,500	15,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=40, crowded=0, essential=0
Levofloxacin Mg	1,800	4,500	11,160	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=49, gap=40, crowded=0, essential=0
Azithromycin Mg	2,700	6,750	16,065	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=44, gap=25, crowded=0, essential=0
Ciprofloxacin Specification	900	2,250	4,815	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=32, gap=60, crowded=0, essential=0
Levofloxacin Hemydrate Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole 0 5 Gm	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole 0 5 W	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Levofloxacin 250mgs	900	2,250	5,084	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=38, gap=60, crowded=0, essential=0
Amoxicillin Base	5,400	13,500	47,250	low	✓	6 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=32, crowded=0, essential=0
Metronidazole Sodium Chloride	900	2,250	5,715	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=52, gap=60, crowded=0, essential=0
Levofloxacin Per100ml Mg	900	2,250	4,770	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=31, gap=60, crowded=0, essential=0
Ciprofloxacin Ciprofloxacin Base Mg	900	2,250	5,535	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=60, crowded=0, essential=0
Amoxicillin Clavulanic Acid 50	900	2,250	6,705	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=74, gap=60, crowded=0, essential=0
Cephalexin B P	900	2,250	5,400	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=45, gap=60, crowded=0, essential=0
Amoxicillintrihydrateequivalenttoamoxcillinbase 50mgpotassiumclavulanateeq Toclavulani	900	2,250	5,535	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=60, crowded=0, essential=0
Doxycycline Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Azithromycin Base Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Cefixime Mg	5,400	13,500	33,210	low	✓	6 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=0, crowded=0, essential=0
Levofloxacin 4	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Azithromycin Base	3,600	9,000	25,020	low	✓	4 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=64, gap=12, crowded=0, essential=0
Azithromycin W	900	2,250	5,625	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=50, gap=60, crowded=0, essential=0
Doxycycline Doxycycline H	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Azithromycin Specification	900	2,250	5,220	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=41, gap=60, crowded=0, essential=0
Amoxicillintrihydrateequivalenttoamoxicillinbase 400mgpotassiumclavulanateeq Toclavulanicaci	900	2,250	5,535	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=48, gap=60, crowded=0, essential=0
Cefixime Specifications 250 Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillin 1 Gm	1,800	4,500	15,750	low	✓	2 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=60, crowded=0, essential=0
Cefixime Trihydate Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Ciprofloxacin W	2,700	6,750	11,205	low	✓	3 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=8, gap=25, crowded=0, essential=0
Ciprofloxacin Equivalentto3 0mgbase	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillin 500mgclavulanicacid	900	2,250	6,705	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=74, gap=60, crowded=0, essential=0
Amoxicillinas 250mgclavulanicacidaspotassium	900	2,250	6,705	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=74, gap=60, crowded=0, essential=0
Metronidazole Base Metronidazole	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazoleasbenzonate200mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Cephalexin Specs	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Levofloxacin 750 Gm	900	2,250	7,875	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=100, gap=60, crowded=0, essential=0
Ciprofloxacin 1 Gm	900	2,250	5,400	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=45, gap=60, crowded=0, essential=0
Cephalexin Mg	900	2,250	6,165	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=62, gap=60, crowded=0, essential=0
Each5mlcontains Azithromycine200mg Each5mlcontains Azithromycine200mg Mg	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Amoxicillin Base 20 Gm	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0
Metronidazole 400mgdiloxanide	900	2,250	3,375	low	✓	1 brands x 500 units/brand/month base \| IQVIA-calibrated: Q1 2025 market=3.77B units, 4.5x scaling; spread=0, gap=60, crowded=0, essential=0